HUTCHMED (00013.HK) announced results from the Phase III part of the ESLIM-02 study of sovleplenib in patients with warm antibody autoimmune hemolytic anemia (wAIHA) in China were ... Open a new ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
(RTTNews) - HUTCHMED (China) Ltd. (HCM), a commercial-stage biopharmaceutical company, is scheduled to present new and updated data from its ESLIM-01 Phase III trial at the American Society of ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HCM) (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that results from ESLIM-01, ...
— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for ...
Hutchmed (China) Limited, an innovative, commercial-stage, biopharmaceutical company, announces that the pivotal phase III trial ESLIM-01 evaluating the investigational use of sovleplenib met its ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
—The ESLIM-02 study underscores sovleplenib’s potential to address critical unmet needs in a treatment landscape currently devoid of approved targeted therapies — Professor Bing Han of Peking Union ...
- plans for regulatory submission underway in china, where it was designated a breakthrough therapy - - results to be submitted to an upcoming medical meeting - hong kong and shanghai, china and ...
— Sovleplenib demonstrated rapid and durable hemoglobin response with favorable safety profile — —The ESLIM-02 study underscores sovleplenib’s potential to address critical unmet needs in a treatment ...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 12, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces results from the Phase III part of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results